| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6c7ad6bc47e3e08eb0d79ecf58a570d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ac5405d6b1cc4de641bd54cd4121164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b23fc96adda0588adeda7356f0250bd1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2005-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c688afe9a56e5c6742f6abece22a3d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3efcf211388d03ce42602dd1bcf0c0fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5217d07daa55e5dd3930deec4bffb1ee |
| publicationDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006051352-A1 |
| titleOfInvention |
CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof |
| abstract |
The present invention relates to differentiation, apoptosis and tumorigenicity. The present invention more particularly relates to compositions comprising ligands which target CEA such that the adhesion, differentiation-Inhibitory and apoptosis-resistance activities (tumorigenic effects) of Ig superfamily member, CEA, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents comprising compositions which reverse the CEA-mediated tumorigenic effects and enable a lowering of the doses of a chemotherapeutic agent. In one embodiment the invention relates to methods of reducing, preventing or reversing CEA-mediated tumorigenic effects comprising a use of an amount of a CEA declustering agent comprising compositions that can reverse a CEA mediated tumorigenic effect. In one embodiment, the invention further relates to compositions comprising a CEA declustering agent for reversing CEA-mediated tumorigenic effects and restoring drug induced apoptosis to human cancer cells and uses thereof. |
| priorityDate |
2004-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |